

For Health Professionals Who Care for Cancer Patients

Inside This Issue:

Editor's Choice

LUAJNIVPC: Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab, CARBOplatin and PACLitaxel

LUAJNIVPP: Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab, Pemetrexed and Platinum

Cancer Drug Manual[®]

New: Pralsetinib **Revised:** Abemaciclib, bortezomib, cladribine, melphalan; Hep B prophylaxis updates: Alemtuzumab, belantamab mafodotin, bortezomib, cladribine, fludarabine, nilotinib, obinutuzumab, ponatinib, rituximab, romidepsin, siltuximab; Chemotherapy and Stability Chart: Paclitaxel-NAB

Continuing Education

Family Practice Oncology Network

Continuing Medical Education: Management of Surgically Induced Menopause

Benefit Drug List

New: LUAJNIVPC, LUAJNIVPP

NEW Protocols, PPPOs and Patient Handouts

LU LUAJNIVPC, LUAJNIVPP

REVISED Protocols, PPPOs and Patient Handouts

BR BRAJACT, BRAJACTG, BRAJACTT, BRAJACTTG, BRAJACTW, BRAJDAC, BRAJDC, BRAJDCARBT, BRAJFECF | **GI** GIGAVFFOXN, UGIPRRT | **GO** GOOVBEVG, GOOVBEVLD, GOOVBEVP, GOOVBEVV | **GU** GUSUNI | **LK** LKMSA, LKMFUX, LKPCVRUX | **LU** ULUAJATZ, LULADUR, LULADUR4 | **LY** LYASPMEDX | **MY** MYDARBD, MYDARLD, UMYISACARD, UMYISAPOMD | **SM** SMAJDT, SMAVDAB, SMAVDT, SMAVEB, SMAVTRA, SMAVVC, SMAVVM

Resources and Contact Information

Editor's Choice

New Programs

Effective 01 February 2024, the BC Cancer Provincial Systemic Therapy Program has approved the following new treatment programs. The full details of these programs can be found on the BC Cancer website in the [Chemotherapy Protocols](#) section.

Lung

Nivolumab in Combination with Platinum-Doublet Chemotherapy for Non-Small Cell Lung Cancer (LUAJNIVPC, LUAJNIVPP) – The BC Cancer Lung Tumour Group is introducing nivolumab with carboplatin and paclitaxel (LUAJNIVPC) or pemetrexed and platinum (LUAJNIVPP) as neoadjuvant treatment for patients with resectable non-small cell lung cancer with tumours size 4 cm or greater, or positive lymph nodes. In the phase III CheckMate 816 study, the addition of nivolumab to neoadjuvant platinum-doublet chemotherapy was shown to improve event-free survival (hazard ratio 0.63) and pathological complete response (24.0% vs 2.2%). Nivolumab was associated with manageable toxicities consistent with the known safety profile.[1]

1. CADTH Reimbursement Recommendation. Nivolumab (Opdivo): in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of adult patients with resectable non-small cell lung cancer (tumours ≥ 4 cm or node positive). April 2023.

All documents are available in the [Cancer Drug Manual[®]](#) on the BC Cancer website.

New Documents

Note that the following drug is not a BC Cancer Benefit Drug and requires application to the BC Cancer Compassionate Access Program (CAP). The corresponding Interim Monograph and Patient Handout are made available for reference only.

The **Pralsetinib Interim Monograph** and **Patient Handout** have been developed with review provided by Megan Darbyshire (tumour group pharmacist, BC Cancer Provincial Pharmacy). Pralsetinib is a RET (REarranged during Transfection) tyrosine kinase inhibitor. It is used in the treatment of RET fusion-positive non-small cell lung cancer (NSCLC). The usual dose is 400 mg orally once daily.

Highlights from these documents include:

- fatal interstitial lung disease (ILD)/pneumonitis has occurred; advise patients to promptly report any new or worsening respiratory symptoms such as cough, dyspnea or fever.
- pralsetinib starting dose adjustment may be required to manage some drug interactions
- serious hepatotoxicity has been reported; patients with hepatic impairment may need increased AST/ALT monitoring
- dispense pralsetinib in original bottle with desiccant; once bottle has been opened, remaining capsules should be discarded after 4 months

Pralsetinib has been added to the **Auxiliary Label List** and was previously evaluated for the **BC Health Authorities Provincial Hazardous Drug List**.

Revised Documents

Abemaciclib

Side Effects table: revised emetogenic potential to LOW to align with new breast protocols (UBRAJABEAI and UBRAJACET)

Bortezomib

Cautions: deleted bullet for Hepatitis B reactivation; added new link for SCHBV protocol

Pregnancy: deleted FDA pregnancy category; added relevant animal data and recommendation for patients

Cladribine

Cautions: deleted standalone paragraph for Hepatitis B reactivation; added new link for SCHBV protocol

Carcinogenicity: added details about human risk and relevant animal data

Fertility: added relevant animal data

Pregnancy: deleted FDA pregnancy category; added relevant animal data and recommendation for patients

Paclitaxel-NAB Chemotherapy Preparation and Stability Chart

NEW: Added generic product

Melphalan Monograph

Cautions: added new link for SCHBV protocol

Fertility: added relevant animal data

Pregnancy: deleted FDA pregnancy category; added relevant animal data

Hepatitis B Prophylaxis has been updated in the following monographs:

| | |
|----------------------|--------------|
| Alemtuzumab | Obinutuzumab |
| Belantamab mafodotin | Ponatinib |
| Bortezomib | Rituximab |
| Cladribine | Romidepsin |
| Fludarabine | Siltuximab |
| Nilotinib | |

Continuing Education

Family Practice Oncology Network Continuing Medical Education

The Family Practice Oncology Network (FPON) is pleased to announce a complimentary accredited webinar session on '**Management of Surgically Induced Menopause**' on **Thursday, 15 February, from 8 am to 9 am**, as part of the ongoing Complimentary Accredited Webinar Series. This session will cover:

- a. indications for and benefits of premenopausal oophorectomy;
- b. acute consequences of premenopausal oophorectomy and management thereof;
- c. long-term consequences, prevention and management approach of oophorectomy;
- d. symptom management in women with increased breast cancer risk.

This session is offered at **no charge** and is accredited at up to 1.0 Mainpro+ credits.

For more information and links to registration, visit the FPON Continuing Medical Education site at fpon.ca or <https://ubccpd.ca/learn/learning-activities/course?eventtemplate=675-fpon-webinar-management-of-surgically-induced-menopause>

Benefit Drug List

New Programs

Effective 01 February 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

| Protocol Title | Protocol Code | Benefit Status |
|--|------------------|----------------|
| Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab , CARBOplatin and PACLitaxel | LUAJNIVPC | Class I |
| Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab , Pemetrexed and Platinum | LUAJNIVPP | Class I |

Revised Programs

Effective 01 February 2024, the following new treatment programs have been added to the BC Cancer [Benefit Drug List](#):

| Protocol Title | Protocol Code | Benefit Status |
|--|-----------------|---------------------------------|
| Treatment of Symptomatic Myelofibrosis with Ruxolitinib | LKMFRUX | Class I (previously Restricted) |
| Treatment of Polycythemia Vera with Ruxolitinib | LKPCVRUX | Class I (previously Restricted) |

List of Revised Protocols, Pre-Printed Orders and Patient Handouts

BC Cancer Protocol Summaries, Provincial Pre-Printed orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below, with document revisions indicated in the respective columns. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter **U**.

NEW Protocols, PPPOs and Patient Handouts (*new documents checked*)

| Code | Protocol Title | Protocol | PPPO | Handout |
|-----------|--|-------------------------------------|-------------------------------------|---------|
| LUAJNIVPC | Neoadjuvant Treatment of Non-Small Cell Lung Cancer with Nivolumab , CARBOplatin and PACLitaxel | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | -- |
| LUAJNIVPP | Neoadjuvant Treatment of Non-Squamous Non-Small Cell Lung Cancer with Nivolumab , Pemetrexed and Platinum | <input checked="" type="checkbox"/> | <input checked="" type="checkbox"/> | -- |

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

| Code | Protocol Title | Protocol | PPPO | Handout |
|--------------------|---|----------|------|---|
| BR Breast | | | | |
| BRAJACT | Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel | -- | -- | <i>Logo, institution name, title, & self-management updated, Use as neoadjuvant therapy added</i> |
| BRAJACTG | Neoadjuvant or Adjuvant Therapy for Breast Cancer using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide followed by PACLitaxel | -- | -- | <i>Logo, institution name, title, & self-management updated, Use as neoadjuvant therapy added</i> |
| BRAJACTT | Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab | -- | -- | <i>Title, & self-management updated, Use as neoadjuvant therapy added</i> |

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

| Code | Protocol Title | Protocol | PPPO | Handout |
|-------------------|---|----------|------|---|
| BRAJACTTG | Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Dose Dense Therapy: DOXOrubicin and Cyclophosphamide Followed by PACLitaxel and Trastuzumab | -- | -- | <i>Title, & self-management updated, Use as neoadjuvant therapy added</i> |
| BRAJACTW | Neoadjuvant or Adjuvant Therapy for Early Breast Cancer Using DOXOrubicin and Cyclophosphamide followed by Weekly PACLitaxel | -- | -- | <i>Logo, institution name, title, & self-management updated, Use as neoadjuvant therapy added</i> |
| BRAJDAC | Neoadjuvant or Adjuvant Therapy for Breast Cancer using Cyclophosphamide, DOXOrubicin and DOCETaxel | -- | -- | <i>Title updated, Use as neoadjuvant therapy added</i> |
| BRAJDC | Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOCETaxel and Cyclophosphamide | -- | -- | <i>Logo, institution name & title, Use as neoadjuvant therapy added</i> |
| BRAJDCARBT | Neoadjuvant or Adjuvant Therapy for Breast Cancer using DOCETaxel, CARBOplatin, and Trastuzumab | -- | -- | <i>Title updated, Use as neoadjuvant therapy added</i> |
| BRAJFCD | Neoadjuvant or Adjuvant Therapy for Breast Cancer Using Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel | -- | -- | <i>Logo, institution name & title updated, Use as neoadjuvant therapy added</i> |

GI | Gastrointestinal

| | | | | |
|-------------------|--|---|--|----|
| GIGAVFFOXN | First-Line Treatment of Locally Advanced or Metastatic Esophageal, Gastroesophageal, or Gastric Cancer using Oxaliplatin, Fluorouracil, Leucovorin and Nivolumab | <i>Typographic error corrected under Note</i> | -- | -- |
| UGIPRRT | Peptide Receptor Radionuclide Therapy (PRRT) using Lutetium 177Lu-Dotatate (LUTATHERA) for Treatment in Patients with Somatostatin Receptor Positive Midgut Neuroendocrine Tumours | <i>Precautions clarified</i> | <i>Clarification of octreotide dose interval</i> | |

GO | Gynecologic

REVISED Protocols, PPPOs and Patient Handouts *(revisions in respective columns)*

| Code | Protocol Title | Protocol | PPPO | Handout |
|---------------------------|--|---|--|---------|
| GOOVBEVG | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Gemcitabine | <i>Title and eligibility updated</i> | -- | -- |
| GOOVBEVLD | Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and DOXOrubicin Pegylated Liposomal | <i>Title and eligibility updated</i> | -- | -- |
| GOOVBEVP | Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and PACLitaxel | <i>Title and eligibility updated</i> | -- | -- |
| GOOVBEVV | Treatment of Platinum Resistant or Refractory Epithelial Ovarian Cancer with Bevacizumab and Vinorelbine | <i>Title and eligibility updated</i> | -- | -- |
| GU Genitourinary | | | | |
| GUSUNI | Palliative Therapy for Renal Cell Carcinoma Using SUNItinib | <i>Eligibility clarified, uric acid, ALT added to baseline tests</i> | -- | -- |
| LK Leukemia | | | | |
| LKMDSA | Therapy of Myelodysplastic Syndrome using Azacitidine | -- | <i>Time of pre-metrics changed to 96 hours</i> | -- |
| LKMFRUX | Treatment of Symptomatic Myelofibrosis with Ruxolitinib | <i>Protocol code revised, CAP requirement deleted, hepatitis B serology and prophylaxis updated</i> | <i>CAP deleted, protocol code updated</i> | -- |
| LKPCVRUX | Treatment of Polycythemia Vera with Ruxolitinib | <i>Protocol code revised, CAP requirement deleted, hepatitis B serology and prophylaxis updated</i> | <i>CAP deleted, protocol code updated</i> | -- |
| LU Lung | | | | |
| ULUAJATZ | Adjuvant Treatment of Resected Non-Small Cell Lung Cancer using Atezolizumab | <i>Exclusions updated</i> | -- | -- |
| LULADUR | Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Durvalumab | <i>Eligibility updated</i> | -- | -- |
| LULADUR4 | Treatment of Locally Advanced Non-Small Cell Lung Cancer Using 4-Weekly Durvalumab | <i>Eligibility updated</i> | -- | -- |
| LY Lymphoma | | | | |
| LYASPMEDX | Treatment of Refractory or Relapsing Extranodal Natural Killer or T-Cell Lymphoma Using Pegaspargase, Methotrexate and Dexamethasone | <i>Premedications updated</i> | -- | -- |
| MY Myeloma | | | | |

REVISED Protocols, PPPOs and Patient Handouts (*revisions in respective columns*)

| Code | Protocol Title | Protocol | PPPO | Handout |
|---------------------------------|--|--|---|---------|
| MYDARBD | Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Bortezomib and Dexamethasone With or Without Cyclophosphamide | <i>Eligibility clarified</i> | -- | -- |
| MYDARLD | Treatment of Relapsed and Refractory Multiple Myeloma with Daratumumab in Combination with Lenalidomide and Dexamethasone With or Without Cyclophosphamide | <i>Eligibility clarified</i> | -- | -- |
| UMYISACARD | Therapy of Multiple Myeloma using Carfilzomib, Dexamethasone and Isatuximab with or without Cyclophosphamide | <i>Eligibility clarified</i> | -- | -- |
| UMYISAPOMD | Therapy of Multiple Myeloma using Pomalidomide, Dexamethasone and Isatuximab with or without Cyclophosphamide | <i>Eligibility clarified</i> | -- | -- |
| SM Skin & Melanoma | | | | |
| SMAJDT | Adjuvant Treatment of Stage III and IV, BRAF mutated, fully resected Melanoma Using daBRAFeinib and Trametinib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVDAB | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVDT | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using daBRAFeinib and Trametinib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVEB | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using Encorafenib and Binimetinib | <i>Tests & dose modification updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVTRA | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using Trametinib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVVC | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma using vemURAFenib and Cobimetinib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |
| SMAVVEM | Treatment of BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma Using vemURAFenib | <i>Tests updated</i> | <i>Treatment, return appointment orders updated</i> | -- |

Resources and Contact Information

| Resource | Phone | Email / Toll Free / Fax |
|---|-----------------------|---|
| Systemic Therapy Update: www.bccancer.bc.ca/health-professionals/clinical-resources/systemic-therapy/systemic-therapy-update | | |
| Systemic Therapy Update Editor | 604-877-6000 x 672649 | bulletin@bccancer.bc.ca |
| Oncology Drug Information | 604-877-6275 | druginfo@bccancer.bc.ca |
| Cancer Drug Manual Editor | 250-519-5500 x 693742 | nbadry@bccancer.bc.ca |
| Pharmacy Oncology Certification | 250-712-3900 x 686820 | rxchemocert@bccancer.bc.ca |
| Nurse Educators | 604-877-6000 x 672638 | nursinged@bccancer.bc.ca |
| CAP – Compassionate Access Program | 604-877-6277 | cap_bcca@bccancer.bc.ca fax 604-708-2026 |
| OSCAR – Online System for Cancer Drugs Adjudication and Reimbursement | 888-355-0355 | oscar@bccancer.bc.ca fax 604-708-2051 |
| Library/Cancer Information | 604-675-8003 | toll free 888-675-8001 x 8003 requests@bccancer.bc.ca |
| Library Document Delivery | 604-675-8002 | requests@bccancer.bc.ca |
| Pharmacy Professional Practice | 604-877-6000 x 672247 | mclin@bccancer.bc.ca |
| Professional Practice, Nursing | 604-877-6000 x 672623 | BCCancerPPNAdmin@ehcnet.phsa.ca |
| Provincial Systemic Therapy Program | 604-877-6000 x 672247 | mclin@bccancer.bc.ca |
| BC Cancer – Abbotsford | 604-851-4710 | toll free 877-547-3777 |
| BC Cancer – Kelowna | 250-712-3900 | toll free 888-563-7773 |
| BC Cancer – Prince George | 250-645-7300 | toll free 855-775-7300 |
| BC Cancer – Surrey | 604-930-2098 | toll free 800-523-2885 |
| BC Cancer – Vancouver | 604-877-6000 | toll free 800-663-3333 |
| BC Cancer – Victoria | 250-519-5500 | toll free 800-670-3322 |
| Community Oncology Network (CON) sites: To update your contact information, please contact: bulletin@bccancer.bc.ca | | |

Editorial Review Board

Mario de Lemos, PharmD, MSc(Oncol) (Interim Editor)
 Jeevan Dosanjh, RN, BScN
 Alina Gerrie, MD, MPH, FRCPC

Samuel Hackett, RN, BScN, CON(C)
 Alison Pow, BScPharm